Fermented Ophiocordyceps sinensis mycelium products for preventing contrast-associated acute kidney injury: a systematic review of randomized controlled trials
Background To evaluate the efficacy, effectiveness and safety of fermented Ophiocordyceps sinensis mycelium (FOSM) products for preventing contrast-associated acute kidney injury (CA-AKI).Methods Randomized controlled trials were searched from four Chinese and four English electronic databases and t...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2023.2300302 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591098238730240 |
|---|---|
| author | Fenglan Pu Tianli Li Chen Shen Yingqiao Wang Chunmei Tang Xiaowen Zhang Lijiao Yan Qihe Xu Jianping Liu |
| author_facet | Fenglan Pu Tianli Li Chen Shen Yingqiao Wang Chunmei Tang Xiaowen Zhang Lijiao Yan Qihe Xu Jianping Liu |
| author_sort | Fenglan Pu |
| collection | DOAJ |
| description | Background To evaluate the efficacy, effectiveness and safety of fermented Ophiocordyceps sinensis mycelium (FOSM) products for preventing contrast-associated acute kidney injury (CA-AKI).Methods Randomized controlled trials were searched from four Chinese and four English electronic databases and three clinical trial registries up to July 2023. Methodological quality was assessed by using the Cochrane risk-of-bias tool 2.0. Risk difference (RD) or risk ratio (RR) and mean difference (MD) were calculated along with the 95% confidence intervals (CIs).Results Fourteen trials testing three types of FOSM products (Bailing, Zhiling, and Jinshuibao capsules) involving 1271 participants injected contrast agents were included. For the risk of bias, all trials were rated as some concerns. Compared with routine preventive procedure (RPP) (saline hydration and alprostadil), FOSM products plus RPP showed beneficial effects in reducing the incidence of CA-AKI (14.62% and 5.35%, respectively; RD −0.06, 95% CI −0.09 to −0.03). Subgroup analysis showed that Bailing/Jinshuibao plus RPP demonstrated lower incidence of CA-AKI compared to RPP. However, there was no statistically significant difference between Zhiling with RPP and RPP in the incidence of CA-AKI. Additionally, only when FOSM products were taken before injection of the contrast, it was superior to RPP in reducing the incidence of CA-AKI. There was no statistical difference in adverse events between these two groups.Conclusions Low certainty evidence suggests that preventive oral use of FOSM products as an adjuvant agent was safe and might decrease the incidence of CA-AKI. However, high-quality placebo-controlled trials are needed to confirm its benefit. |
| format | Article |
| id | doaj-art-60db5af0d2004ec7b351179d24d78101 |
| institution | Kabale University |
| issn | 0886-022X 1525-6049 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Renal Failure |
| spelling | doaj-art-60db5af0d2004ec7b351179d24d781012025-01-23T04:17:49ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492024-12-0146110.1080/0886022X.2023.2300302Fermented Ophiocordyceps sinensis mycelium products for preventing contrast-associated acute kidney injury: a systematic review of randomized controlled trialsFenglan Pu0Tianli Li1Chen Shen2Yingqiao Wang3Chunmei Tang4Xiaowen Zhang5Lijiao Yan6Qihe Xu7Jianping Liu8Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, ChinaNational Integrated Traditional and Western Medicine Center for Cardiovascular Disease, China-Japan Friendship Hospital, Beijing, ChinaCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, ChinaSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, ChinaDepartment of Reproductive Medicine, Suzhou Hospital of Traditional Chinese Medicine, Suzhou, ChinaCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, ChinaInstitute of Basic Clinical Medicine of Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, ChinaCentre for Integrative Chinese Medicine and Department of Renal Medicine, King’s College London, London, UKCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, ChinaBackground To evaluate the efficacy, effectiveness and safety of fermented Ophiocordyceps sinensis mycelium (FOSM) products for preventing contrast-associated acute kidney injury (CA-AKI).Methods Randomized controlled trials were searched from four Chinese and four English electronic databases and three clinical trial registries up to July 2023. Methodological quality was assessed by using the Cochrane risk-of-bias tool 2.0. Risk difference (RD) or risk ratio (RR) and mean difference (MD) were calculated along with the 95% confidence intervals (CIs).Results Fourteen trials testing three types of FOSM products (Bailing, Zhiling, and Jinshuibao capsules) involving 1271 participants injected contrast agents were included. For the risk of bias, all trials were rated as some concerns. Compared with routine preventive procedure (RPP) (saline hydration and alprostadil), FOSM products plus RPP showed beneficial effects in reducing the incidence of CA-AKI (14.62% and 5.35%, respectively; RD −0.06, 95% CI −0.09 to −0.03). Subgroup analysis showed that Bailing/Jinshuibao plus RPP demonstrated lower incidence of CA-AKI compared to RPP. However, there was no statistically significant difference between Zhiling with RPP and RPP in the incidence of CA-AKI. Additionally, only when FOSM products were taken before injection of the contrast, it was superior to RPP in reducing the incidence of CA-AKI. There was no statistical difference in adverse events between these two groups.Conclusions Low certainty evidence suggests that preventive oral use of FOSM products as an adjuvant agent was safe and might decrease the incidence of CA-AKI. However, high-quality placebo-controlled trials are needed to confirm its benefit.https://www.tandfonline.com/doi/10.1080/0886022X.2023.2300302Chinese patent medicineOphiocordyceps sinensiscontrast-associated acute kidney injuryrandomized clinical trialssystematic review |
| spellingShingle | Fenglan Pu Tianli Li Chen Shen Yingqiao Wang Chunmei Tang Xiaowen Zhang Lijiao Yan Qihe Xu Jianping Liu Fermented Ophiocordyceps sinensis mycelium products for preventing contrast-associated acute kidney injury: a systematic review of randomized controlled trials Renal Failure Chinese patent medicine Ophiocordyceps sinensis contrast-associated acute kidney injury randomized clinical trials systematic review |
| title | Fermented Ophiocordyceps sinensis mycelium products for preventing contrast-associated acute kidney injury: a systematic review of randomized controlled trials |
| title_full | Fermented Ophiocordyceps sinensis mycelium products for preventing contrast-associated acute kidney injury: a systematic review of randomized controlled trials |
| title_fullStr | Fermented Ophiocordyceps sinensis mycelium products for preventing contrast-associated acute kidney injury: a systematic review of randomized controlled trials |
| title_full_unstemmed | Fermented Ophiocordyceps sinensis mycelium products for preventing contrast-associated acute kidney injury: a systematic review of randomized controlled trials |
| title_short | Fermented Ophiocordyceps sinensis mycelium products for preventing contrast-associated acute kidney injury: a systematic review of randomized controlled trials |
| title_sort | fermented ophiocordyceps sinensis mycelium products for preventing contrast associated acute kidney injury a systematic review of randomized controlled trials |
| topic | Chinese patent medicine Ophiocordyceps sinensis contrast-associated acute kidney injury randomized clinical trials systematic review |
| url | https://www.tandfonline.com/doi/10.1080/0886022X.2023.2300302 |
| work_keys_str_mv | AT fenglanpu fermentedophiocordycepssinensismyceliumproductsforpreventingcontrastassociatedacutekidneyinjuryasystematicreviewofrandomizedcontrolledtrials AT tianlili fermentedophiocordycepssinensismyceliumproductsforpreventingcontrastassociatedacutekidneyinjuryasystematicreviewofrandomizedcontrolledtrials AT chenshen fermentedophiocordycepssinensismyceliumproductsforpreventingcontrastassociatedacutekidneyinjuryasystematicreviewofrandomizedcontrolledtrials AT yingqiaowang fermentedophiocordycepssinensismyceliumproductsforpreventingcontrastassociatedacutekidneyinjuryasystematicreviewofrandomizedcontrolledtrials AT chunmeitang fermentedophiocordycepssinensismyceliumproductsforpreventingcontrastassociatedacutekidneyinjuryasystematicreviewofrandomizedcontrolledtrials AT xiaowenzhang fermentedophiocordycepssinensismyceliumproductsforpreventingcontrastassociatedacutekidneyinjuryasystematicreviewofrandomizedcontrolledtrials AT lijiaoyan fermentedophiocordycepssinensismyceliumproductsforpreventingcontrastassociatedacutekidneyinjuryasystematicreviewofrandomizedcontrolledtrials AT qihexu fermentedophiocordycepssinensismyceliumproductsforpreventingcontrastassociatedacutekidneyinjuryasystematicreviewofrandomizedcontrolledtrials AT jianpingliu fermentedophiocordycepssinensismyceliumproductsforpreventingcontrastassociatedacutekidneyinjuryasystematicreviewofrandomizedcontrolledtrials |